A Trial of Durvalumab and Tremelimumab in Comibination With SBRT in Patients With Metastatic Cancer

Conditions:   Head and Neck Squamous Cell Carcinoma;   Lung Cancer;   Oesophageal Cancer
Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Radiation: SBRT
Sponsor:   Gustave Roussy, Cancer Campus, Grand Paris
Recruiting - verified July 2017

http://ift.tt/2sLAfqA